<DOC>
	<DOCNO>NCT02378688</DOCNO>
	<brief_summary>The primary objective study : - To evaluate safety tolerability MT-1303 subject moderate severe active Crohn 's Disease（CD） - To evaluate clinical efficacy MT-1303 subject moderate severe active CD .</brief_summary>
	<brief_title>Safety Efficacy MT-1303 Subjects With Moderate Severe Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosis CD ( involve small intestine and/or colon ) , confirm endoscopy histopathology least 3 month prior Visit 1 Previous use type corticosteroid immunosuppressant treatment CD Moderate severe active CD define CDAI score ≥220 ≤450 point Visit 1 Diagnosis ulcerative colitis , indeterminate colitis , pseudomembranous colitis coeliac disease Enterocutaneous , abdominal pelvic active fistula , abscesses fistulae likely require surgery study GI surgery ( include appendectomy ) within 12 week prior Visit 2 ( Baseline ) surgery plan deemed likely require surgery CD study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>